Arecor Therapeutics Plc · LSE:AREC
Arecor Therapeutics — H1 2023 Earnings Presentation
22 slides from Arecor Therapeutics's earnings presentation, Sep 14, 2023
Slide 1: Advancing today's therapies to enable healthier lives
Advancing today’s therapies to enable healthier lives Interim results for the six months ended 30 June 2023 14 September 2023 www.arecor.com
Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or
Slide 3: Presentation Team
Presentation Team Dr Sarah Howell We are focused on improving Chief Executive Officer patient care by enhancing existing therapeutic medicines to bring safer, more effective and convenient treatments to Susan Lowther patients Chief Financial Officer Page 2 Arecor 2023 | Confidential
Slide 4: Building value through better patient care
Building value through better patient care Combining in-house development with partnered portfolio offer potential for significant revenue generation Establishing new products Clinical development Commercial focus/Marketed products Proprietary Technology In-house Licensed Tetris Pharma Licensed Pipe
Slide 5: A broad portfolio of de-risked development and commercial products
A broad portfolio of de-risked development and commercial products Balanced portfolio of commercial and development assets offering optionality on partnering and revenue growth potential Current Product Area Research Preclinical Phase I Phase II Phase III Est launch market size AT278 Diabetes 2026 A
Slide 6: Operational highlights (including post-period events)
Operational highlights (including post-period events) Building towards a significant self-sustaining biopharmaceutical company Significant partnership progression In-house proprietary pipeline • AT307 transferred to Hikma triggering milestone • AT278 – Second Phase I clinical trial in people with pa
Slide 7: Capturing long term value through partnerships
01 Capturing long term value through partnerships Page 6 Arecor 2023 | Confidential
Slide 8: Significant progress on AT307 with partner Hikma
Significant progress on AT307 with partner Hikma de-risking development and bringing product closer to market Under milestone and royalty bearing license agreement Q420 Q123 Q323 2024+ Arecor enters co-dev & Hikma exercises license right Hikma positive pre-IND Additional development license agreemen
Slide 9: Licensed partnered products moving closer to market launch
Licensed partnered products moving closer to market launch Generating near-term and longer term revenues from development milestones and commercial royalty payments AT220 * Undisclosed partner AT292 (INHBRX-101) • Partner has taken key regulatory steps towards commercialisation for this product inco
Slide 10: Best-in-class insulins for more effective treatment of diabetes
01 Best-in-class insulins for more effective treatment of diabetes Page 9 Arecor 2023 | Confidential
Slide 11: Diabetes in crisis: There is still a need for improved insulins
Diabetes in crisis: There is still a need for improved insulins A major worldwide health issue with significant unmet needs in diabetes care 537 million adults are living with diabetes $966 billion 6.7 million estimated global deaths due to diabetes expenditure in 2021 Page 10 Arecor 2023 | Confiden
Slide 12: AT247 Potential to enable transformational fully closed loop artificial pancreas
AT247 Potential to enable transformational fully closed loop artificial pancreas Ultra-rapid acting 100U/mL insulin to improve quality and life and outcomes for Type 1 diabetic patients CGM Measures blood glucose levels in real-time Successful completion of two Phase I clinical studies AP ‘holy grai
Slide 13: AT278 500 U/mL: Creating a disruptor insulin
AT278 500 U/mL: Creating a disruptor insulin Potential to be the first concentrated ultra-rapid insulin (URI) product available to patients The need AT278 potential to be first and • Growing number of type 2 diabetics requiring high daily doses of insulin (>100U/day) potentially only ultra- concentr
Slide 14: The future - AT278 enabled next generation miniaturised, longer wear pump
The future - AT278 enabled next generation miniaturised, longer wear pump Miniaturisation and extended wear is not possible without an ultra-concentrated, ultra-rapid insulin AT278 + next generation insulin pump Simplify care and improve outcomes Potential to revolutionise treatment by reducing dise
Slide 15: AT278 Second clinical trial first patient dosed Mar 2023
AT278 Second clinical trial first patient dosed Mar 2023 Potential to become gold standard insulin for people with diabetes with high daily insulin needs • Initiated January 2023, first patient dosed March 2023 • Phase I randomised, double-blind study in adult patients with type 2 diabetes • Each pa
Slide 16: Tetris Pharma
04 Tetris Pharma Page 15 Arecor 2023 | Confidential
Slide 17: Tetris Pharma continues to deliver with Ogluo sales growth
Tetris Pharma continues to deliver with Ogluo® sales growth • Continued success of European commercial roll-out of Key diabetes product Ogluo® Ogluo® • Post Arecor acquisition demonstrating Ogluo sales growth Ready-to-use glucagon for • Made available in 3 new territories within 1H 23 – Austria, eme
Slide 18: Financials and newsflow
04 Financials and newsflow Page 17 Arecor 2023 | Confidential
Slide 19: 2023 H1 financial highlights
2023 H1 financial highlights Key financials Revenue base expanding to • Revenue increased by 141% to £1.7m (H1 2022: £0.7m) product sales, licenses, • Total income increased by 103% to £2.3m (H1 2022: £1.1m) milestones and royalties • Investment in R&D of £2.9m (H1 2022: £4.8m) • Loss after tax of £
Slide 20: Key financials
Key financials Focus on delivering consistent year-on-year revenue growth £’m H1 2023 H1 2022 Doubling of total income • Revenue from 2 new formulation projects, Formulation development 0.4 0.7 signed post period, will be recognized July onwards Milestone 0.1 - • Hikma milestone triggered in January
Slide 21: Significant upcoming milestones to drive growth
Significant upcoming milestones to drive growth Existing licensing and new licensing upside potential 2023 2024 2025 onwards • AT307 transfer to HIK & license milestone • Significant potential returns from license • Multiple products under license and and positive FDA feedback from pre-IND meeting a
Slide 22: Thank you
Contact Sarah Howell, CEO sarah.howell@arecor.com Susan Lowther, CFO susan.lowther@arecor.com Thank you www.arecor.com